The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis

Cancer Treatment Reviews

Volumn 30, Issue 1, 2004, Pages 83-101

  Bastiaannet, E ^a   Groen, B ^a   Jager, P L ^a   Cobben, D C P ^a   van der Graaf, W T A ^a   Vaalburg, W ^a   Hoekstra, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bone sarcomas; Diagnostic value; FDG PET; Meta analysis; Position emission tomography; Sarcomas; Soft tissue sarcomas; Systematic review

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADVANCED CANCER; BENIGN TUMOR; CANCER GRADING; CLINICAL TRIAL; COCHRANE LIBRARY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EMBASE; HUMAN; INFORMATION PROCESSING; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METHODOLOGY; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; RADIOLOGICAL PARAMETERS; REVIEW; SENSITIVITY AND SPECIFICITY; SOFT TISSUE SARCOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE METABOLISM;

EID: 1242307295     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2003.07.004     Document Type: Article

References (50)

1. Eary JF, Conrad EU, Bruckner JD, Folpe A, Hunt KJ, Mankoff DA, et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4:1215-20.
2. Visser O, Coebergh JWW, van Dijck JAAM, Siesling S. Incidence of cancer in the Netherlands 1998. Utrecht: vereniging van Integrale Kankercentra: Drukkerij De Kempen Druk; 2002.
3. Enzinger FM, Weiss SW. Soft tissue tumors. 4th ed. St. Louis Missouri: Mosby; 2002. 1-26.
4. Komdeur R, Hoekstra HJ, van den Berg E, Molenaar WM, Pras E, de Vries EGE, et al. Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. Cancer Meta Rev 2002;21:167-83.
5. Lawrence Jr W, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 1987;205:349-59.
6. Nijhuis PH, Schaapveld M, Otter R, Molenaar WM, van der Graaf WT, Hoekstra HJ. Epidemiological aspects of soft tissue sarcomas (STS) - consequences for the design of clinical STS trials. Eur J Cancer 1999;35: 1705-10.
7. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22-30.
8. el Zeftawy H, Heiba SI, Jana S, Rosen G, Salem S, Santiago JF, et al. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma. Cancer Biother Radiopharm 2001;16:37-46.
9. Huth JF, Eilber FR. Patterns of metastatic spread following resection of extremity soft-tissue sarcomas and strategies for treatment. Semin Surg Oncol 1988;4:20-6.
10. Potter DA, Glenn J, Kinsella T, Glatstein E, Lack EE, Restrepo C, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol 1985;3: 353-66.
11. Kole AC, Nieweg OE, van Ginkel RJ, Pruim J, Hoekstra HJ, Paans AM, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann Surg Oncol 1997;4:57-63.
12. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980;21:670-5.
13. Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Inform Assoc 1994;1:447-58.
14. Deville WL, Bezemer PD, Bouter LM. Publications on diagnostic test evaluation in family medicine journals: an optimal search strategy. J Clin Epidemiol 2000;53:65-9.
15. Hunt DL, McKibbon KA. Locating and appraising systematic reviews. Ann Intern Med 1997;126:532-8.
16. Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001;91:1530-42.
17. Vroomen PC, de Krom MC, Knottnerus JA. Diagnostic value of history and physical examination in patients suspected of sciatica due to disc herniation: a systematic review. J Neurol 1999;246:899-906.
18. Sackett DL. Clinical epidemiology. Am J Epidemiol 1969;89:125-8.
19. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003;138:W1-W12.
20. Irwig L, Tosteson AN, Gatsonis C, Lau J, Colditz G, Chalmers TC, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 1994;120:667-76.
21. Lachs MS, Nachamkin I, Edelstein PH, Goldman J, Feinstein AR, Schwartz JS. Spectrum bias in the evaluation of diagnostic tests: lessons from the rapid dipstick test for urinary tract infection. Ann Intern Med 1992; 117:135-40.
22. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061-6.
23. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, et al. Clinical value of [18-F]fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000;231:380-6.
24. Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988;29:181-6.
25. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996;23:1409-15.
26. van Ginkel RJ, Hoekstra HJ, Pruim J, Nieweg OE, Molenaar WM, Paans AM, et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 1996; 37:984-90.
27. Adler LP, Blair HF, Williams RP, Pathria MN, Makley JT, Joyce MJ, et al. Grading tiposarcomas with PET using [18F]FDG. J Comput Assist Tomogr 1990;14:960-2.
28. Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2001; 2:659-66.
29. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18-FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.
30. Lucas JD, O'Doherty MJ, Wong JC, Bingham JB, McKee PH, Fletcher CD, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 1998;80: 441-7.
31. Umesaki N, Tanaka T, Miyama M, Kawamura N, Ogita S, Kawabe J, et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001;80:372-7.
32. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, et al. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001;42:713-20.
33. Lucas JD, O'Doherty MJ, Cronin BF, Marsden PK, Lodge MA, McKee PH, et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999;86:550-6.
34. Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AM, Molenaar WM, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37: 257-61.
35. Schwarzbach MH, Dimitrakopoulou-Strauss A, Mechtersheimer G, Hinz U, Willeke F, Cardona S, et al. Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET). Anticancer Res 2001;21:3609-14.
36. Schwarzbach M, Willeke F, Dimitrakopoulou-Strauss A, Strauss LG, Zhang YM, Mechtersheimer G, et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Res 1999;19:1343-9.
37. Franzius C, Daldrup-Link HE, Sciuk J, Rummeny EJ, Bielack S, Jurgens H, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: Comparison with spiral CT. Ann Oncol 2001;12:479-86.
38. Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000;27: 1305-11.
39. Aoki J, Watanabe H, Shinozaki T, Tokunaga M, Inoue T, Endo K. FDG-PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr 1999;23:603-8.
40. Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000;25:874-81.
41. Hawkins DS, Rajendran JG, Conrad III EU, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F- 18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 2002;94:3277-84.
42. Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999;40:1637-43.
43. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998;39:250-4.
44. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med 1999;26:599-605.
45. Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jurgens H, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-36.
46. Garcia R, Kim EE, Wong FC, Korkmaz M, Wong WH, Yang DJ, et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996;37:1476-9.
47. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000;41: 1695-701.
48. Folpe AL, Lyles RH, Sprouse JT, Conrad III EU, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000; 6:1279-87.
49. Griffeth LK, Dehdashti F, McGuire AH, McGuire DJ, Perry DJ, Moerlein SM, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D- glucose. Radiology 1992; 182:185-94.
50. Jones DN, McCowage GB, Sostman HD, Brizel DM, Layfield L, Charles HC, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 1996; 37:1438-44.